BLUE Bluebird bio Inc

USD 1.22 0.00 0
Icon

Bluebird bio Inc (BLUE) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Under-perform

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 1.22

0.00 (0.00)%

USD 0.24B

6.31M

USD 2.93(+139.75%)

USD 10.13 (+730.33%)

Icon

BLUE

Bluebird bio Inc (USD)
COMMON STOCK | NSD
USD 1.22
0.00 0
Take a Tour
stockTargetAdvisor

Under-perform

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 0.24B

USD 10.13 (+730.33%)

USD 1.22

Bluebird bio Inc (BLUE) Stock Forecast

Show ratings and price targets of :
USD 2.93
(+139.75%)

Based on the Bluebird bio Inc stock forecast from 4 analysts, the average analyst target price for Bluebird bio Inc is USD 2.93 over the next 12 months. Bluebird bio Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Bluebird bio Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Bluebird bio Inc’s stock price was USD 1.22. Bluebird bio Inc’s stock price has changed by +32.13% over the past week, +27.14% over the past month and -59.74% over the last year.

No recent analyst target price found for Bluebird bio Inc
No recent average analyst rating found for Bluebird bio Inc

Company Overview Bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassem...Read More

https://www.bluebirdbio.com

455 Grand Union Boulevard, Somerville, MA, United States, 02145

323

December

USD

USA

Adjusted Closing Price for Bluebird bio Inc (BLUE)

Loading...

Unadjusted Closing Price for Bluebird bio Inc (BLUE)

Loading...

Share Trading Volume for Bluebird bio Inc Shares

Loading...

Compare Performance of Bluebird bio Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLUE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bluebird bio Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing BLUE

Symbol Name BLUE's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Bluebird bio Inc (BLUE) Stock

Based on ratings from 4 analysts Bluebird bio Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, 1 sell and 3 hold ratings.

Unfortunately we do not have enough data on BLUE's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for BLUE is USD 2.93 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 1.02.

Unfortunately we do not have enough data on BLUE's stock to indicate if its overvalued.

The last closing price of BLUE's stock was USD 1.22.

The most recent market capitalization for BLUE is USD 0.24B.

Based on targets from 4 analysts, the average taret price for BLUE is projected at USD 2.93 over the next 12 months. This means that BLUE's stock price may go up by +139.75% over the next 12 months.

We can't find any ETFs which contains Bluebird bio Inc's stock.

As per our most recent records Bluebird bio Inc has 323 Employees.

Bluebird bio Inc's registered address is 455 Grand Union Boulevard, Somerville, MA, United States, 02145. You can get more information about it from Bluebird bio Inc's website at https://www.bluebirdbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...